AstraZeneca cut to Neutral at Credit Suisse; says valuation reflects oncology prospects
Credit Suisse downgraded AstraZeneca (AZN) to Neutral from Outperform Thursday, arguing that the company shares, following a strong YTD performance, already reflect the company’s…
AstraZeneca cut to Neutral at Credit Suisse; says valuation reflects oncology prospects
Credit Suisse downgraded AstraZeneca (AZN) to Neutral from Outperform Thursday, arguing that the company shares, following a strong YTD performance, already reflect the company’s…